Lung Cancer

Skip to main content

Lung Cancer

Metastatic Non–Small-Cell Lung Cancer with Targetable Mutations

Geoff Oxnard, MD

FDA Updates, Lung Cancer

Gavreto, a New RET Inhibitor, FDA Approved for Metastatic NSCLC with RET Fusions

Lung Cancer

Durvalumab in Combination with Chemotherapy as First-Line Treatment for Extensive-Stage SCLC (CASPIAN Data)

Lung Cancer

Platinum Doublet Chemotherapy plus Pembrolizumab for Patients with SCLC: KEYNOTE-604

Lung Cancer

Cediranib Combined with Olaparib in Patients with Platinum-Pretreated SCLC

Lung Cancer

Lurbinectedin for Second-Line Treatment of Patients with Metastatic SCLC

Lung Cancer

Real-World Data for Nivolumab in Patients with Malignant Mesothelioma

Lung Cancer

Trastuzumab Deruxtecan in Patients with HER2-Mutated Advanced NSCLC

Lung Cancer

Pralsetinib and Selpercatinib for NSCLC Patients with RET Gene Fusions

Lung Cancer

Lorlatinib Improves Outcomes Over Crizotinib in First-Line Setting of ALK-Positive NSCLC

5
6
7
8
9
10
11

Page 8 of 12
Results 71 - 80 of 116